Published online Jun 14, 2005. doi: 10.3748/wjg.v11.i22.3457
Revised: February 3, 2004
Accepted: February 21, 2004
Published online: June 14, 2005
AIM: To introduce the basic methods of gray relational analysis (GRA) and to illustrate its applications in gastroenterology.
METHODS: With the essential formulae of GRA and several typically practical examples, the procedure of GRA was introduced. Examples were drawn from the gastroenterological studies. Thus the trait of GRA could be demonstrated.
RESULTS: The superiority of GRA in gastroenterological study was proved by the examples.
CONCLUSION: GRA can be applied mechanically or flexibly in gastroenterology.
- Citation: Tan XR, Li YG, Chen MZ. Applications of gray relational analysis in gastroenterology. World J Gastroenterol 2005; 11(22): 3457-3460
- URL: https://www.wjgnet.com/1007-9327/full/v11/i22/3457.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i22.3457
Gray relational analysis (GRA) was initiated by Professor Ju-Long Deng, the famous scientist and founder of gray system theory, Huazhong University of Science and Technology[1]. Previous applications of GRA in medical researches were mostly in cardiology[2-7]. In our viewpoint, it is very useful to introduce GRA to gastroenterologists.
Let X be the gray relational factor set, x0∈X be the consulting sequence, xi∈X (i = 1, 2,…, m; m≥2, as the comparative factors) be the comparative sequence, x0 and xi are named factor sequences. The x0(k) and xi(k) are the values of x0 and xi at k point (k = 1, 2,…, n; n≥3). Thus, the formulae of gray relational coefficient γ(x0(k), xi(k)) and gray relational grade γ(x0,xi) are as Math 1 shows.
Math 1
The gray relational order, based on the gray relational grade γ(x0,xi) which represents the strength of relationship between x0 and xi, can be constructed. In the formula, Math 2 and Math 3 are the absolute values of the minimum and maximum from the differences between xi(k) and x0(k). xi(k) and x0(k) are the values at point k in the x0 and xi, the sequences without dimension. Here, ζ = 0.5.
Math 2
Math 3
Dis-dimension method Let x=(x(1), x(2),…, x(n)) be the sequence with dimension. Thus, f:x→χ, Math 4.
Math 4
Evaluation matrix of GRA Suppose x0j∈x0 be a group of the consulting factors, j = 1, 2,…, e. Thus, there is the gray relational matrix R about x0 and xi as Math 5 shows
Math 5
GRA model of clinical trial Let xi∈X, xi=(xi(1), xi(2),…, xi(n)) be the observing parameter sequences of group i or case i; i=1, 2,…, m, m≥2, as the number of trial group or trial case.
Let x0∈X, x0 = (x0(1), x0(2),…, x0(n)) be the ideal parameter sequence of trial, the ideal values used to construct x0 are chosen from xi. Here, k= 1, 2,…, n, n≥3, as the number of parameters in the sequences. Hence, the gray relational grade g(x0,xi) acts as the reflection of approaching the ideal effects. Then, the formulae as Math 6 shows are called GRA model of clinical trial.
Math 6
GRA on small sample data background The objective of this study was to evaluate the relationship between the baseline condition of patients with alveococcosis and the therapeutic effects by using albendazole regularly. Four patients with complete data who were diagnosed clinically and complicated by obstructive jaundice were enrolled in this study. Albendazole was orally given twice daily for over 1 year with a dosage of 20 mg/kg each day in all cases. Baseline values of the observation parameters are shown in Table 1. The effects of albendazole on hepatic functions are shown in Table 2.
No. (k) | Age (yr) (x1) | Course of jaundice (mo) (x2) | Toughness degree of liver (x3) | Liver below costal arch (cm) (x4) | Liver below xiphoid (cm) (x5) | Splenomegaly (cm) (x6) |
1 | 55 | 5.0 | 3 | 3 | 6 | 0 |
2 | 43 | 2.0 | 2 | 3 | 7 | 1 |
3 | 27 | 0.7 | 2 | 6 | 4 | 4 |
4 | 48 | 1.0 | 3 | 2 | 0 | 2 |
No. (k) | Bilirubin (mmol/L) (x7) | One minute bilirubin (mmol/L) (x8) | ALP (IU) (x9) | GOT (x10) | A/G (g/L) (x11) | |||||
Before | After | Before | After | Before | After | Before | After | Before | After | |
1 | 89.2 | 14.2 | 11.3 | 2.1 | 176.6 | 28.4 | 30.0 | 30.0 | 45.5/37.5 | 44.2/27.5 |
2 | 60.2 | 8.9 | 8.0 | 0.5 | 58.0 | 51.0 | 76.0 | 30.0 | 41.0/56.0 | 45.1/33.9 |
3 | 62.0 | 8.9 | 23.4 | 0.9 | 481.0 | 10.6 | 72.0 | 63.0 | 28.0/54.0 | 48.0/36.0 |
4 | 212.9 | 17.0 | 129.2 | 1.9 | 463.0 | 247.0 | 135.0 | 30.0 | 33.0/45.0 | 45.0/27.0 |
Analysis Step 1: To calculate the improved ratio of hepatic functions. The improved ratio was calculated by using the formula as Math 7 shows.
Math 7
Here, r = improved ratio, a = parameter value before treatment, b = parameter value after treatment.
The calculated values of the improved ratio are listed in Table 3.
k | x7 | x8 | x9 | x10 | x11 |
1 | 0.84081 | 0.81416 | 0.83902 | 0.00000 | 0.32468 |
2 | 0.85216 | 0.93750 | 0.12069 | 0.60526 | 0.81711 |
3 | 0.98074 | 0.96154 | 0.97796 | 0.12500 | 1.57141 |
4 | 0.92015 | 0.98529 | 0.46652 | 0.77778 | 1.27274 |
Step 2: Correlation analysis Let x7-x11 be the dependent variables, let x1-x6 be the independent variables, correlation analysis was performed using the statistical analysis system (version 6.12). The results of correlation analysis are shown in Table 4, indicating that the correlation between dependent variables and independent variables was not significant.
x7 | x8 | x9 | x10 | x11 | |
x1 | -0.81774 | -0.59309 | -0.27907 | 0.10911 | -0.77759 |
0.1823 | 0.4069 | 0.7209 | 0.8909 | 0.2224 | |
x2 | -0.78666 | -0.98054 | 0.15755 | -0.56181 | -0.98954 |
0.2133 | 0.0195 | 0.8425 | 0.4382 | 0.0105 | |
x3 | -0.31909 | -0.37737 | 0.15463 | 0.06341 | -0.45498 |
0.6809 | 0.6226 | 0.8454 | 0.9366 | 0.5450 | |
x4 | 0.66573 | 0.12652 | 0.63044 | -0.59213 | 0.40379 |
0.3343 | 0.8735 | 0.3696 | 0.4079 | 0.5962 | |
x5 | -0.56410 | -0.60064 | -0.11905 | -0.52589 | -0.57561 |
0.4359 | 0.3994 | 0.8810 | 0.4741 | 0.4244 | |
x6 | 0.97814 | 0.72219 | 0.38317 | 0.03476 | 0.90090 |
0.0219 | 0.2778 | 0.6168 | 0.9652 | 0.0991 |
Step 3: GRA Let x0j∈x0 be a group of the consulting factors, j = 7, 8, 9, 10, 11 as the consulting factors, let x1-x6∈xi, i = 1, 2, 3, 4, 5, 6 be the comparative factors. GRA was operated by using GRA program that we edited in the statistical analysis system (version 6.12). Dis-dimension process was the averaging method. Thus, the gray relational matrix R about x0 and xi is as Math 8 shows.
Math 8
The GRA results revealed in the gray relational factor set that the superior consulting factors were x7 and x8, the superior comparative factors were x1, x3 and x4.
Background The purpose of this project was to evaluate the effects of four therapeutic strategies on duodenal ulcer (DU) related to Helicobacter pylori (H pylori). Forty-nine male and nine female patients with DU were complicated by H pylori-positivities proved by endoscopic examination and H pylori test, and had no gastric or complex ulcer. Their ages were 24-62 years (average 37.1±6.5 years). All the subjects had no obvious complications or other systemic disorders. They did not take antibiotics, bismuth agents or restrain acids/antacids for 2 wk preceding the study.
Step 1: Data collection Grouping and therapeutic strategies: All the subjects were randomly divided into four groups. Group A had 14 cases that were treated with a triple therapeutic strategy of tinidazole (Livzon), Lizhu Dele/colloidal bismuth subcitrate (Livzon Pharmaceutical Factory, Zhuhai) and omeprazole (Sanye Pharm). Group B had 14 cases that were treated with a triple therapeutic strategy of metronidazole (Tongji Meiji), amoxicillin (Baiyunshan, Guangzhou) and omeprazole (Sanye Pharm). Group C had 14 cases that were treated with a triple therapeutic strategy of metronidazole (Tongji Meiji), amoxicillin (Baiyunshan, Guangzhou) and De-Nol/colloidal bismuth subcitrate (Yamanouchi Europe). Group D had 15 cases that were treated with a single therapeutic strategy of omeprazole (Sanye Pharm). There were no significant differences between groups in age or sex distribution. The dose of tinidazole was 1.0 mg b.i.d, Lizhu Dele/colloidal bismuth subcitrate 110 mg q.i.d, omeprazole 20 mg q.d, amoxicillin 0.5 mg q.i.d, metronidazole 0.2 mg t.i.d, De-Nol/colloidal bismuth subcitrate 120 mg q.i.d. Lizhu Dele/colloidal bismuth subcitrate and De-Nol/colloidal bismuth subcitrate were taken orally 30 min ante cibum or before sleep. The others were taken orally 30 min post cibum. Lizhu Dele/colloidal bismuth subcitrate, De-Nol/colloidal bismuth subcitrate and omeprazole were given for 2 wk and the others for 1 wk.
Endoscopic examination and H pylori test All the subjects underwent endoscopic examination and H pylori test. After pharynx local anesthesia, gastroduodenal endoscopy was performed in all subjects taking a left lateral position by Q30 electronic endoscope system. Images were screened and rinsed, washing-cell specimen muter representatives were taken from the site of ulcer lesion during endoscopy. At normal temperature, the specimen muter representatives were put in the H pylori fast test box containing reagents (the PLA Higher Medical School, Lanzhou, China). After 24 h, the reagents that appeared in rose were defined as positive, and those that remained unchanged in color were defined as negative.
Estimation criteria All patients were asked to return for a check-up in a month after treatment. They were evaluated under four aspects: (1) Disappearance of symptoms (all baseline symptoms including pyrosis, epigastric pain, abdominal distension, acid suffusion and belching of gas, etc. disappeared). (2) Eradication of H pylori (the specimen muter representatives in H pylori test double boxes became negative, and one of them being positive was thought that eradication of H pylori infection was not achieved). (3) Active mucitis fading (the original hyperemia, erosion, edema in the duodenal mucosa were not seen endoscopically). (4) Ulcer cure (the duodenal ulcer vanished or pitted, and abated, dilated or unchanged ulcers in the ulcer area were defined as uncured).
Step 2: Raw data of four groups are listed in Table 5.
Group (i) k | n | n | Disappearance of symptoms | Eradication of H pylori | Active mucitis fading | Ulcer cure | ||||
Rate (%) (1) | Time (d) (2) | n | Rate (%) (3) | n | Rate (%) (4) | n | Rate (%) (5) | |||
A (x1) | 14 | 14 | 100 | 3.8 | 11 | 78.6 | 9/13 | 69.2 | 12 | 85.7 |
B (x2) | 15 | 15 | 100 | 3.6 | 10 | 66.7 | 9/13 | 69.2 | 11 | 73.3 |
C (x3) | 14 | 10 | 71.4a | 6.8 | 11 | 78.6 | 9/12 | 75 | 9 | 64.3 |
D (x4) | 15 | 15 | 100 | 3.7 | 2 | 13.3b | 3/12 | 25 | 9 | 60 |
Ideal (x0) | 100 | 3.6 | 78.6 | 75 | 85.7 |
Step 3: GRA Let the ideal sequence x0, x0(k)∈x0, k = 1, 2, 3, 4, 5, be the consulting factor sequences. Let xi, xi(k)∈xi, i = 1, 2, 3, 4, 5, 6, be the comparative factor sequences. GRA was operated using GRA program that we edited in the statistical analysis system (version 6.12). Thus, the gray relational coefficients between x0 and xi are as follows (Table 6).
Group (i) k | Disappearance of symptoms | Eradication of H pylori | Active mucitis fadin | Ulcer cure | |
Rate (%) (1) | Time (d) (2) | Rate (%) (3) | Rate (%) (4) | Rate (%)(5) | |
A (1) | 1 | 0.9175 | 1 | 0.8481 | 1 |
B (2) | 1 | 1 | 0.7328 | 0.8481 | 0.7547 |
C (3) | 0.6302 | 0.4099 | 1 | 1 | 0.6407 |
D (4) | 1 | 0.9569 | 0.3333 | 0.3932 | 0.6013 |
The gray relational grades to ideals of four groups were:
γ0A, i.e., γ01 = 0.95312; γ0B, i.e., γ02= 0.86712; γ0C, i.e., γ03 = 0.73616; γ0D, i.e., γ04 = 0.65694.
Thus the gray relational order was x1>x2>x3>x4; i.e., strategy Astrategy Bstrategy Cstrategy D.
Background Serum procollagen type III (PC III), prolidase (PLD), and hyaluronic acid (HA), are of diagnostic significance in liver fibrosis. To find out the markers with early diagnostic value of liver fibrosis via GRA, 100 patients with chronic liver diseases including 28 patients with chronic persistent hepatitis (CPH), 21 patients with chronic active hepatitis (CAH), and 51 patients with liver cirrhosis (LC), were studied. Thirty HBVM-negative subjects with normal liver biochemical test served as controls. The clinical materials of the subjects are listed in Table 7.
Groups | Number of subjects | Age (yr) | Number of males |
Controls | 30 | 31.7±7.2 | 19 |
CPH | 28 | 35.2±9.1 | 20 |
CAH | 21 | 34.9±6.9 | 16 |
LC | 51 | 45.11±1.4 | 41 |
Clinical materials Examination of PC III, PLD and HA PC III was assayed by using a commercially available radioimmunoassay (Chongqing Institute of Phymatosis, Chongqing). The activity of PLD was assayed by using a commercially available ultraviolet spectrophotometry (Third Military Medical University, Chongqing). Serum HA was assayed by using a commercially available radioimmunoassay (Shanghai Institute of Navy Medicine, Shanghai). PC III, PLD and HA in controls were regarded as the normal upper limits, and the sensitivity of each marker was calculated. The results are shown in Table 8.
Marker | CPH | CAH | LC |
PC III | 28.6 | 100.0 | 88.2 |
PLD | 0.0 | 57.1 | 90.2 |
HA | 7.1 | 76.2 | 94.2 |
GRA Step 1: To construct the ideal sequence The ideal sequence was constructed according to the pathological changes of liver diseases. There was no liver fibrosis in CPH, and so the sensitivity of an ideal marker value for the diagnosis of CPH should be zero. Whereas there was early liver fibrosis in CAH, and so the sensitivity of an ideal marker value for CAH should be 100%. The average value of the sensitivity of PC III, PLD and HA in LC was 90.9%, which can be chosen as the sensitivity of an ideal marker value for LC. So, the ideal sequence was x0 = (0, 100, 90.9).
Step 2: To identify the comparative sequences The observed parameter sequences of i (i = 1, 2, 3 = sensitivity of PC III, sensitivity of PLD and sensitivity of HA) were xi, x1, x2, x3∈xi. Thus, the parameter sequences were x1 = (28.6, 100, 88.2), x2 = (0, 57.1, 90.2), x3 = (7.1, 76.2, 94.2), which served as the comparative sequences. x0, xi∈X, was the GAR factor set.
Step 3: GRA operation GRA was performed using the GRA program that we edited in the statistical analysis system (version 6.12). The results were: γ (x0,x1) = 0.7733, γ (x0,x2) = 0.7667, γ (x0,x3) = 0.7. So the gray relational order was:γ(x0,x1)>γ(x0,x2)>γ(x0,x3); i.e., x1x2x3.
In conclusion, The GRA showing superiority to statistical methods in some cases can be applied mechanically or flexibly in gastroenterology.
Through GRA, serum PC III was identified as the marker with early diagnostic value of liver fibrosis. This example provides a new insight into the study of liver diseases and illustrates a practical application of GRA.
Since the discovery of H pylori in 1983, a wealth of data about DU related to H pylori has been accumulated, and the therapeutic strategies of duodenal ulcer have been changed. There is evidence that ulcer cure and reduction of recurrence could be achieved by effective antibiotic therapy. Such colloidal bismuth subcitrates as Lizhu Dele or De-Nol can form a protective bismuth-protein membrane which can promote healing of the ulcer and prevent recurrence of ulcer. The results of GRA showed that the gray relational order of the comprehensive effects in terms of the symptom disappearance, eradication of H pylori, active mucitis fading and ulcer cure is strategy Astrategy Bstrategy Cstrategy D, and strategy A is the best of four strategies which showed no differences from the previous reports.
Alveococcosis is as harmful as a malignant tumor. Untreated cases had a 5-year mortality rate of 70% and 10-year of 93%. The severity is related to jaundice. Patients with alveococcosis had a low diagnostic and hospitalization rate. There is a shortage of clinical samples, and not suitable for statistical analysis. The first time report on alveococcosis had no statistical analysis. The GRA results indicated that jaundice parameter bilirubin and 1-min bilirubin were the superior consulting factors, which suggest the main effect of albendazole on alveococcosis. The relevant factors with severity of the disease such as age, degree of liver toughness and liver below costal arch were the superior comparative factors, which suggest that the effects of albendazole on alveococcosis were partially restricted by the baseline conditions of patients. This example provides objective evidence and demonstrates that GRA is superior to statistical analysis for small sample data.
1. | Deng JL. Introduction to grey system theory. J Grey System. 1989;1:1-24. [Cited in This Article: ] |
2. | Huang WD, Shi HR, Tan XR. A grey relational study on determination of stroke volume with D and M echocardiography. J Grey System. 1994;6:203-211. [Cited in This Article: ] |
3. | Tan XR, Deng JL, Huang WD, Wang ZL. GRA on plasma ET-1, PAP, PaO2 and PaCO2 in the elderly patients with PHD. In: Liu SF, Xu ZX. Huise Xitong Yanjiu Jinzhan Huazhong LiGong Daxue Chubanshe Wuhan China 1996; 133-135. [Cited in This Article: ] |
4. | Xu YC, Tan XR. Grey relational analysis of a trial of trental vs antiaggregants. J Grey System. 1997;9:365-370. [Cited in This Article: ] |
5. | Tan XR, Yang YH, Deng JL. Grey relational analysing factors in hypertensive with cardiac insufficiency. J Grey System. 1998;10:75-80. [Cited in This Article: ] |
6. | Tan XR, Deng JL, Chu YJ. Grey relational analysis of circadian variation of plasma renin activity, angiotensin II and blood pressure in hypertensives. J Grey System. 1999;11:41-46. [Cited in This Article: ] |
7. | Tan XR, Yang HS, Chu YJ. Superior grey relational analysis on cardiac structure and function with blood pressure in systolic hypertension. International Symposium on Hypertension and Related Diseases Chinese Hypertension League Chinese Society of Cardiology & Chinese Academy of Medical Science Beijing-Langfang China 1999: 135. . [Cited in This Article: ] |